These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19369120)

  • 1. Alteration of tight junctions in intestinal transplantation induced by Campath-1H.
    Li Q; Zhang Q; Wang C; Li Y; Li Y; Li N; Li J; Wu B; Liu X
    Clin Immunol; 2009 Jul; 132(1):141-3. PubMed ID: 19369120
    [No Abstract]   [Full Text] [Related]  

  • 2. CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.
    Shah A; Lowenstein H; Chant A; Khan A
    Transpl Int; 2006 Sep; 19(9):749-58. PubMed ID: 16918536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Campath-1H induced pure red cell aplasia in a patient with chronic lymphatic leukaemia.
    Thachil J; Salim R
    Leuk Res; 2007 Jul; 31(7):1025-6. PubMed ID: 17005249
    [No Abstract]   [Full Text] [Related]  

  • 4. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation.
    Tzakis AG; Kato T; Nishida S; Levi DM; Madariaga JR; Nery JR; Mittal N; Regev A; Cantwell P; Gyamfi A; Weppler D; Miller J; Tryphonopoulos P; Ruiz P
    Transplantation; 2003 Apr; 75(8):1227-31. PubMed ID: 12717207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Campath-1H in intestinal and multivisceral transplantation: preliminary data.
    Tzakis AG; Kato T; Nishida S; Levi D; Madariaga J; De Faria W; Nery J; Neff G; Kirk AD; Ruiz P
    Transplant Proc; 2002 May; 34(3):937. PubMed ID: 12034248
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).
    Walsh M; Chaudhry A; Jayne D
    Ann Rheum Dis; 2008 Sep; 67(9):1322-7. PubMed ID: 18055469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.
    Abad S; Gyan E; Moachon L; Bouscary D; Sicard D; Dreyfus F; Blanche P
    Clin Infect Dis; 2003 Jul; 37(2):e27-8. PubMed ID: 12856232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.
    Lockwood CM; Hale G; Waldman H; Jayne DR
    Rheumatology (Oxford); 2003 Dec; 42(12):1539-44. PubMed ID: 12949252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Campath-1H.
    Sorokin P
    Clin J Oncol Nurs; 2001; 5(2):65-6. PubMed ID: 11899778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia.
    Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
    Br J Haematol; 2006 Nov; 135(4):475-85. PubMed ID: 16995884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
    Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
    J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction therapy for adult small bowel transplant with Campath-1H.
    Nishida S; Levi D; Kato T; Madariaga J; Nery J; Tzakis A
    Transplant Proc; 2002 Aug; 34(5):1889-91. PubMed ID: 12176616
    [No Abstract]   [Full Text] [Related]  

  • 13. Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
    Coles A; Deans J; Compston A
    Clin Neurol Neurosurg; 2004 Jun; 106(3):270-4. PubMed ID: 15177782
    [No Abstract]   [Full Text] [Related]  

  • 14. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood.
    Lowenstein H; Shah A; Chant A; Khan A
    Transpl Int; 2006 Nov; 19(11):927-36. PubMed ID: 17018129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
    Trzonkowski P; Zilvetti M; Friend P; Wood KJ
    Transplantation; 2006 Nov; 82(10):1342-51. PubMed ID: 17130784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody therapeutics and risk for infection.
    Gea-Banacloche JC; Weinberg GA
    Pediatr Infect Dis J; 2007 Nov; 26(11):1049-52. PubMed ID: 17984814
    [No Abstract]   [Full Text] [Related]  

  • 17. CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond.
    Dumont FJ
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):23-35. PubMed ID: 12113063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.
    Keating MJ; Cazin B; Coutré S; Birhiray R; Kovacsovics T; Langer W; Leber B; Maughan T; Rai K; Tjønnfjord G; Bekradda M; Itzhaki M; Hérait P
    J Clin Oncol; 2002 Jan; 20(1):205-13. PubMed ID: 11773171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
    Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocyte depletion and repopulation in peripheral blood and small intestine of cynomolgus monkeys after alemtuzumab treatment.
    Shan T; Qu L; Zhang J; Li Q; Shen B; Gu L; Jiang J; Feng X; Li N; Li J
    J Surg Res; 2011 May; 167(1):e21-7. PubMed ID: 20888596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.